|
Theravance Announces Data From the RELOVAIR(TM) Program to Be Presented at the …
MarketWatch (press release) A total of 13 preclinical and clinical abstracts for RELOVAIR(TM) and its individual components in COPD and asthma were accepted by ERS for presentation, … |
View full post on asthma – Google News